Kezar Life Sciences Q2 Earnings Exceed Expectations, Cash Reserves Down

Kezar Life Sciences reported Q2 GAAP EPS of -$1.87, beating estimates by $0.42. Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024, primarily due to cash used in operations.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases, has reported its financial results for the second quarter of 2025. The company's GAAP EPS of -$1.87 beat estimates by $0.42, according to a press release issued on July 2, 2025.

The company's cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024. This decrease was primarily due to cash used in operations. The company also reported a net loss of $13.7 million for the second quarter, compared to a net loss of $21.5 million for the same period in 2024.

Research and development (R&D) expenses decreased by $6.7 million to $9.6 million in the second quarter of 2025, primarily due to the completion and closeout of clinical trials, a decrease in personnel costs, and a decrease in facility-related expenses. General and administrative (G&A) expenses also decreased by $0.6 million to $5.0 million, primarily due to a decrease in non-cash stock-based compensation and personnel-related expenses.

Zetomipzomib, a selective immunoproteasome inhibitor being evaluated for autoimmune hepatitis, remains a key focus for Kezar Life Sciences. The company is committed to working closely with the FDA to align on the next trial design for zetomipzomib, which is proposed as a registration-enabling study. The company also announced the promotion of Zung To to Chief Development Officer, who brings 35 years of industry experience to the role.

For more information, visit [Kezar Life Sciences](https://www.kezarlifesciences.com).

References:
[1] https://www.marketscreener.com/news/kezar-life-sciences-reports-second-quarter-2025-financial-results-and-provides-business-update-ce7c51d8d889f123
[2] https://seekingalpha.com/news/4484964-kezar-life-sciences-gaap-eps-of-1_87-beats-by-0_42